GLP-1 Hair Loss: What 1 Million Patient Records Reveal
GLP-1 Hair Loss: What 1 Million Patient Records Reveal
The Short Answer
- 40% higher odds of hair loss at 12 months in GLP-1 users vs matched non-users, from a 2025 real-world cohort of nearly 1.1 million patients. [3]
- Women carry most of the risk — semaglutide doubled the hazard of coded alopecia in women (HR 2.08); the male signal was statistically uninformative. [2]
- Alopecia roughly doubles above 20% total body weight loss — 5.3% vs 2.5% in the Wegovy product monograph, pointing at weight loss velocity rather than the drug molecule. [1]
- Semaglutide has the strongest signal among GLP-1s — FAERS reporting odds ratio 2.46 vs tirzepatide 1.73; dulaglutide, liraglutide, and exenatide show no significant signal. [1]
- Most cases are reversible telogen effluvium, but a subset of semaglutide-associated androgenetic alopecia may persist after discontinuation and warrants dermatology evaluation. [1]
A woman three months into semaglutide posted a photo of her hairbrush with the caption: "30 pounds down, 30% of my hair gone." Her post became one of the most repeated stories in GLP-1 online communities — weight dropping on schedule, the drug working, and hair coming out in clumps.
Hair loss is one of the top 15 side-effect questions across GLP-1 forums. Until recently, doctors didn't have much data to answer with. That changed in 2025, when three peer-reviewed studies — including one with over a million patient records — measured the risk for the first time. The short answer: these medications raise the odds of hair loss by about 40% at 12 months. Most of it is temporary shedding triggered by rapid weight loss. Some of it might not be.
What does the research actually say?
The largest study is Vidal and colleagues' 2025 paper in JAAD International. They used a nationwide database covering over 100 million patients across 67 health systems, identified 547,993 adults on GLP-1 drugs, and matched them one-to-one with non-users on age, sex, race, BMI, and diabetes status. They excluded anyone with known hair loss causes like thyroid disease, menopause, or chemotherapy. [3]
higher risk of telogen effluvium at 12 months
This is the kind of shedding where hair comes out in clumps in the shower — not bald patches. It typically starts 3–6 months after rapid weight loss begins and usually reverses once your weight stabilizes.
Women appear to carry most of the risk. A separate 2025 study of over 3,200 people found women on semaglutide had roughly double the hair loss risk of women taking a different weight-loss drug. For men, only one case appeared in each arm — not enough to say anything meaningful either way. [2]
A systematic review pulled together five studies, including the big tirzepatide trial (SURMOUNT-1). In that trial, about 5 out of every 100 people on tirzepatide reported hair loss, compared to about 1 out of 100 on placebo. [1]
| Scenario | Hair loss rate |
|---|---|
| Tirzepatide (any dose) | 4.9–5.3% |
| Placebo pill | 0.9% |
| Semaglutide, patients losing >20% body weight | 5.3% |
| Semaglutide, patients losing <20% body weight | 2.5% |
Look at those last two rows. Hair loss roughly doubles when weight loss crosses 20% of body weight. That's the biggest clue — the real culprit is probably the speed and size of weight loss, not the drug molecule itself.
Where does community wisdom diverge from research?
"The drug is attacking my hair follicles directly."
The main cause is rapid weight loss, which your body treats as a stress event — and responds to by pausing hair growth. That's why the risk jumps sharply when weight loss crosses 20%, regardless of which specific GLP-1 drug you're on.
Myth 1: Hair loss always starts in the first month
People often blame the first few weeks of starting semaglutide. The biology says otherwise. This type of shedding takes 2–4 months to show up — hair follicles have to finish their resting phase before the shedding becomes visible. In the big cohort study, shedding wasn't even significantly elevated at 6 months. It became significant at 12 months. If you're shedding at week 3, the drug is probably not the cause.
Myth 2: Your hair always grows back after you stop the drug
For most people with shedding-type hair loss, yes — once your weight stabilizes and you're eating enough, it reverses and hair regrows. But there's a second pattern: pattern hair loss linked to hormonal shifts that may persist. The first type grows back. The second type might not.
Myth 3: All GLP-1 drugs carry the same risk
They don't. Safety database analyses show semaglutide has the strongest hair loss signal, tirzepatide is elevated but less so, and the older drugs (dulaglutide, liraglutide, exenatide) don't show a significant signal at all. [1]
Hair loss roughly doubles when weight loss crosses 20% of body weight.
Practical protocol
Protein deficiency is one of the biggest drivers of shedding during weight loss. Because these drugs suppress appetite for everything equally, most people under-eat protein without realizing it. Build protein into the meals where you feel least nauseous.
Example: if you weigh 165 lbs (75 kg), aim for about 105 g/day — roughly 30–35 g at each of three meals.
Ask your doctor to check iron, ferritin, vitamin D, zinc, and B12. Low ferritin (your body's iron storage number) is one of the most commonly missed causes of shedding. You can have normal red blood cells and still have ferritin low enough to trigger hair loss.
The research clearly shows hair loss doubles when you cross 20% total body weight lost. If shedding is really bothering you, talk to your doctor about a slower dose increase or holding at a lower dose. This applies whether you're on weekly injections or daily oral semaglutide — the underlying issue is how fast you're losing weight, not how you take the medication.
Your perception of hair density in the mirror can mislead you. A monthly photo from the same angle, parted the same way, gives you real data. Bring those photos to a dermatologist if you end up needing one.
Most shedding from rapid weight loss resolves within a year. If you're still losing significant hair after month 9, that's a signal to see a dermatologist. Pattern hair loss is much more treatable when you catch it early.
What would your doctor tell you?
Your doctor is focused on the outcomes with the biggest impact: weight trajectory, blood sugar, cardiovascular risk. For most people on GLP-1s, those numbers are the real story of treatment. Hair changes are rarely a reason to stop — but they're a legitimate quality-of-life concern, and the research on this is new enough that most standard appointments haven't caught up with it yet.
Dose-day eating: On a weekly shot, most people feel the strongest appetite suppression 24–48 hours after the injection. On daily oral semaglutide, it peaks a couple of hours after the morning pill and wears off through the day. Use your hungrier windows to get protein in. Skipping meals on low-appetite days compounds the underlying cause of shedding.
The most commonly missed issue: Low ferritin. Ask specifically for the ferritin number, not just a general iron panel.
Worth asking about: A dermatologist can do a 10-minute scalp exam called trichoscopy that distinguishes temporary shedding from early pattern hair loss. The treatment paths are very different, so knowing which one you have matters.
Three months into semaglutide, a woman on r/Semaglutide posted a photo of her hairbrush — more shredded than shed — with the caption: "30 pounds down, 30% of my hair gone. Is this ever going to stop?" Her post became one of the most repeated stories across the GLP-1 communities: weight dropping on schedule, the drug working, and hair coming out in clumps that fill the shower drain every morning.
The community data is unambiguous: in a 2026 analysis of 2,100+ GLP-1 forum posts, "hair loss" ranks among the top 15 side-effect questions, with an average engagement score above 1,000 — meaning each post draws substantially more replies and upvotes than the community average. Until recently, clinicians had thin data to answer patients with; alopecia appeared in RCT adverse-event tables but was never a prespecified endpoint. That changed in 2025, when three peer-reviewed analyses — including a real-world matched cohort of over one million patients — quantified the signal for the first time in rigorous fashion.
The headline finding: GLP-1 receptor agonists raise the odds of non-scarring alopecia by roughly 40% at 12 months. Most of it is telogen effluvium — triggered by rapid weight loss — and usually reversible once weight stabilizes. Some of it, in a subset of semaglutide users, may not be.
What does the research actually say?
The strongest signal to date comes from Vidal et al. 2025, a retrospective cohort built on the TriNetX US Collaborative Network, spanning 67 healthcare organizations and more than 100 million patient records from 2014 to 2024. The authors identified 547,993 adults on GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, or tirzepatide) and propensity-score matched them 1:1 with non-users on age, sex, race/ethnicity, BMI, and type 2 diabetes status. Patients with known hair loss confounders — thyroid disease, menopause, chemotherapy, bariatric surgery, malnutrition, ovarian dysfunction, connective tissue disease, scarring alopecias, or trichotillomania — were excluded. This is the largest real-world dermatologic analysis of GLP-1 drugs ever performed. [3]
telogen effluvium at 12 months (95% CI 1.34–2.32)
The 6-month signal was not statistically significant — telogen effluvium has a built-in 3–6 month latency after the precipitating event, and the epidemiologic curve tracks that biology precisely.
A separate temporal trend analysis in the same paper spanned 2014–2024 and showed incidence curves for GLP-1 users and controls running in parallel until approximately 2019, then diverging sharply after 2021–2022, coinciding with mass adoption of high-dose semaglutide and tirzepatide. Both cohorts showed a 2020 spike attributable to the well-documented COVID-19 alopecia wave, but the post-2022 divergence is a natural experiment implicating the newer, higher-potency agents rather than the GLP-1 class generically.
The sex-specific signal surfaces most sharply in Sodhi et al. 2025, a pharmacoepidemiologic study of 1,926 semaglutide users compared to 1,348 bupropion-naltrexone users drawn from the IQVIA PharMetrics Plus database, using an active comparator design to isolate drug-specific effects. In women, semaglutide more than doubled the hazard of coded alopecia (adjusted HR 2.08; 95% CI 1.17–3.72; p<0.05). The overall HR was 1.52 with CI crossing 1.0. In men, only one event occurred per arm — the data cannot address the male question at all. [2]
Why does the sex difference look so extreme?
Three factors likely drive the female skew. First, baseline telogen effluvium prevalence is higher in women due to estrogen-sensitive follicle biology and post-partum shedding patterns already embedded in the female hair cycle. Second, rapid weight loss is a well-established trigger for androgenetic alopecia in genetically predisposed women via reduced sex hormone-binding globulin and increased free androgen availability. Third, women seek care for hair changes at much higher rates than men, producing diagnostic ascertainment bias in ICD-coded outcomes. The Sodhi cohort had 81.4% female users in the comparator arm vs 53.3% in the semaglutide arm, which complicates the overall analysis but makes the sex-stratified female finding the most methodologically clean estimate available.
A third study — Alsuwailem et al. 2025, the first PRISMA systematic review on GLP-1 hair loss — synthesized five heterogeneous studies including SURMOUNT-1 pivotal RCT data. In SURMOUNT-1, tirzepatide caused alopecia in 5.1% at the 5 mg dose, 5.3% at 10 mg, and 4.9% at 15 mg — compared to 0.9% on placebo. That represents a roughly 5-to-6-fold increase in absolute alopecia rates, although hair loss was reported as a spontaneous adverse event rather than a prespecified endpoint and therefore likely undercounts true incidence. [1]
| Drug / Dose | Alopecia rate | Context |
|---|---|---|
| Tirzepatide 5–15 mg (SURMOUNT-1) | 4.9–5.3% | RCT spontaneous AE reporting |
| Placebo (SURMOUNT-1) | 0.9% | RCT spontaneous AE reporting |
| Semaglutide — patients losing >20% body weight | 5.3% | Wegovy product monograph |
| Semaglutide — patients losing <20% body weight | 2.5% | Wegovy product monograph |
| Semaglutide (FAERS disproportionality) | ROR 2.46 | Godfrey 2024 |
| Tirzepatide (FAERS disproportionality) | ROR 1.73 | Godfrey 2024 |
| Dulaglutide / liraglutide / exenatide (FAERS) | No signal | Godfrey 2024 |
The final four rows of that table tell the mechanistic story. Alopecia roughly doubles when total weight loss exceeds 20% — a clean dose-response pattern pointing at the weight loss itself as the proximate cause, not the drug molecule. And among the individual drugs, the strongest FAERS disproportionality signals are attached to the two agents (semaglutide, tirzepatide) that produce the largest and fastest weight loss at their approved doses.
Where does community wisdom diverge from research?
"GLP-1s cause hair loss — the drug literally attacks your follicles."
The dominant mechanism is telogen effluvium secondary to rapid weight loss. Wegovy monograph data shows 5.3% alopecia in patients losing >20% body weight vs 2.5% in those losing less. SURMOUNT-1 showed dose-related rates tracking with weight loss magnitude. GLP-1 receptors are expressed in hair follicles (List 2006), so a direct drug effect cannot be ruled out — but the human data points primarily at weight loss velocity and nutritional status.
Myth 1: Hair loss always starts in the first month
Community posts often attribute shedding to the first few weeks on semaglutide. The underlying biology disagrees. Telogen effluvium has a 2–4 month latency — follicles need to complete their telogen transition before shedding becomes grossly visible on a pillow or in a shower drain.
What do the 6-month vs 12-month numbers actually show?
In Vidal 2025, the telogen effluvium signal was not significant at 6 months but reached aOR 1.76 (95% CI 1.34–2.32) at 12 months. Androgenetic alopecia was already elevated at 6 months (aOR 1.62; 95% CI 1.24–2.12) — consistent with earlier hormonal-shift-driven follicular miniaturization rather than stress-triggered shedding. If you start noticeable shedding at week 3, the cause is almost always something other than the drug itself: seasonal shedding, concurrent stress, iron deficiency, or a missed thyroid diagnosis.
Myth 2: If you stop the drug, your hair always grows back
Telogen effluvium is typically reversible once the trigger resolves, which covers most GLP-1-associated cases. But the Alsuwailem review notes a separate mechanism — semaglutide-associated androgenetic alopecia driven by hormonal changes — where case reports and FAERS narratives suggest the hair loss may persist after discontinuation. The distinction matters enormously: one pattern recovers; the other accelerates an underlying genetic trajectory. A dermatologist can usually differentiate the two on clinical exam.
Myth 3: All GLP-1s carry the same risk
The pharmacovigilance analyses diverge sharply by drug. FAERS disproportionality by Godfrey et al. found semaglutide had an ROR of 2.46 and tirzepatide 1.73 for alopecia — while dulaglutide, liraglutide, and exenatide did not generate a significant signal. In Burke et al.'s retrospective cohort of 283 dermatology patients, semaglutide carried an odds ratio of 6.97 for any hair loss vs other GLP-1 RAs. Tirzepatide in that same cohort was more specifically associated with telogen effluvium (p=0.008). [1]
Alopecia roughly doubles when total weight loss exceeds 20% — the clue points at weight loss velocity, not the molecule.
Practical protocol
Protein deficiency is an independent driver of follicle dysfunction during rapid weight loss. Because GLP-1 medications suppress intake broadly — not selectively against junk food — most users under-eat total protein long before they notice. Front-load protein into the least-nauseous window of your day rather than spreading it thin.
Example: 75 kg × 1.4 = ~105 g/day, ideally distributed across 3 meals of 30–35 g each to hit the leucine threshold that triggers muscle and follicle protein synthesis.
These five markers cover the most common nutritional drivers of shedding during caloric restriction. Ferritin specifically <40 ng/mL is a well-documented precipitant of telogen effluvium independent of absolute iron status or hemoglobin. Many patients with ongoing shedding have a normal iron panel and an unrequested ferritin in the 20–30 range.
The Wegovy dose-response data shows alopecia doubles above 20% total body weight loss. If shedding is bothersome, discussing a slower titration — or holding the current dose rather than advancing — with your prescriber will likely do more than any topical intervention. This applies to both weekly injectable regimens and daily oral semaglutide; the mechanism is weight loss velocity, not delivery route.
Hair density changes are easy to misperceive in the mirror and easy to catastrophize in the shower. A monthly parted-hair photo from the same angle, under the same lighting, gives you data that matters more than subjective shower counts. Bring the log to any dermatology visit — it shortens the diagnostic workup considerably.
Telogen effluvium not resolving by month 9–12 — or any widening part line / receding temporal hairline pattern — warrants workup. Distinguishing reversible TE from early androgenetic alopecia requires clinical exam plus trichoscopy, and early AGA is substantially more treatable than late AGA. This is the single highest-value referral you can request at this stage of the conversation.
What would your doctor tell you?
Your prescriber is tracking the outcomes that carry the largest absolute risk: weight trajectory, HbA1c, lipid panel, cardiovascular markers. For most patients on GLP-1s, those numbers are the real story of the treatment. Hair changes are rarely the reason to stop therapy — but they are a real quality-of-life concern, and the research here is recent enough that standard appointment templates haven't fully caught up with it. That's the gap we can help fill.
Dose-day eating: On a weekly injection, appetite suppression peaks 24–48 hours post-dose and weakens toward days 5–7. On daily oral semaglutide, it peaks within 2–4 hours of the morning pill and fades through the afternoon. Use the hungrier windows — day 5–7 for weekly regimens, late afternoon and evening for oral — to protein-load. Skipping meals on suppressed-appetite days silently compounds the protein and micronutrient deficits that drive shedding.
The diagnostic trap: Low ferritin is the most commonly missed driver of ongoing shedding in GLP-1 users. A normal hemoglobin does not rule it out. Request the ferritin number specifically rather than relying on a generic iron panel — you can be anemia-negative with ferritin in the 20–40 range where telogen effluvium begins.
Worth asking for: A dermatology trichoscopy exam if shedding persists past 9 months. The distinction between resolving TE and emerging AGA can usually be made at the bedside, and the treatment paths diverge sharply from that point.
Get the GLP-1 Guide for This Topic
Our research-backed guide covering key findings, practical strategies, and evidence-based recommendations from the studies cited in this article.
Free PDF · No spam · Unsubscribe anytime
Clinical citations
- Alsuwailem OA, et al. "Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review." Cureus. 2025. Full text
- Sodhi M, Rezaeianzadeh R, Kezouh A, Frey C, Etminan M. "Risk of Hair Loss with Semaglutide for Weight Loss." medRxiv (preprint). 2025. Full text
- Vidal S, et al. "Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide-1 Receptor Agonists: A Real-World Multicentre Cohort Study." JAAD International. 2025. Full text
Get the GLP-1 Guide for This Topic
Key findings, practical strategies, and evidence-based recommendations — backed by the clinical studies cited above. Free PDF, straight to your inbox.
Free PDF · No spam · Unsubscribe anytime
Medical disclaimer
MetaBa content is educational and does not replace medical advice, diagnosis, or treatment from a licensed clinician. Always consult with your healthcare provider before making changes to your diet, exercise, or medication regimen.
Methodology: Community insights synthesized from 2,100+ posts across r/Ozempic, r/Mounjaro, r/Zepbound, r/GLP1, and r/semaglutide. Clinical claims cite peer-reviewed research with linked sources. Reddit quotes paraphrased and anonymized per platform terms.
